The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 980.00
Bid: 983.60
Ask: 984.00
Change: 1.20 (0.12%)
Spread: 0.40 (0.041%)
Open: 985.00
High: 987.40
Low: 979.60
Prev. Close: 978.80
SN. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition

5 Jan 2016 07:00

RNS Number : 7712K
Smith & Nephew Plc
05 January 2016
 

 

 

 

Smith & Nephew completes acquisition of surgical robotics business Blue Belt Technologies

 

5 January 2016

 

 

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces it has completed the acquisition of Blue Belt Holdings, Inc. ("Blue Belt Technologies"), securing a leading position in the fast-growing area of orthopaedic robotics-assisted surgery.

 

Blue Belt Technologies' Navio surgical system currently provides robotics-assistance in unicondylar or partial knee replacement surgery through CT-free navigation software and a unique hand-held, robotic bone-shaping device. Navio and Smith & Nephew's partial knee implant portfolio form a strong combined business from which to accelerate growth in this attractive area of surgery. Additionally, the Group intends to expand the Navio platform into total knee, bi-cruciate retaining knee and revision knee implants, delivering significant further upside.

 

Enquiries

 

InvestorsIngeborg ØieSmith & Nephew

 +44 (0) 20 7960 2285

 

Financial MediaCharles ReynoldsSmith & Nephew

+44 (0) 20 7401 7646

 

Ben Atwell / Matthew ColeFTI Strategic Consulting

 

+44 (0) 20 3727 1000

 

Trade Media

Joe Metzger

Smith & Nephew

 

 

+1 (978) 749-1330

 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

 

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

 

◊Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAKFLEEDKEFF
Date   Source Headline
10th Nov 20207:00 amRNSTotal Voting Rights
3rd Nov 202010:00 amRNSDirector/PDMR Shareholding
2nd Nov 20205:04 pmRNSDirector/PDMR Shareholding
2nd Nov 20202:45 pmRNSTotal Voting Rights
29th Oct 20203:05 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSTrading Statement
20th Oct 202010:00 amRNSKatarzyna Mazur-Hofsaess joins Smith+Nephew as NED
15th Oct 202011:52 amRNSDividend Declaration
9th Oct 20209:08 amRNSNotice of Results
8th Oct 20207:00 amRNSSmith+Nephew Prices USD Bond Issue
1st Oct 202011:08 amRNSTotal Voting Rights
1st Oct 20207:00 amRNSTrading Statement
29th Sep 20201:04 pmRNSExtremities Acquisition
15th Sep 20204:56 pmRNSDirector/PDMR Shareholding
10th Sep 202010:26 amRNSAdditional Listing
1st Sep 20202:00 pmRNSTotal Voting Rights
27th Aug 202011:00 amRNSDirector/PDMR Shareholding
25th Aug 202012:00 pmRNSDirector/PDMR Shareholding
24th Aug 202012:00 pmRNSDirector/PDMR Shareholding
19th Aug 20202:00 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:30 pmRNSBlock listing Interim Review
3rd Aug 202011:59 amRNSTotal Voting Rights
31st Jul 20203:30 pmRNSDirector/PDMR Shareholding
29th Jul 20207:00 amRNSHalf-year Report
13th Jul 202010:45 amRNSDirector/PDMR Shareholding
8th Jul 20208:06 amRNSNotice of Results
1st Jul 202011:09 amRNSTotal Voting Rights
1st Jul 20207:00 amRNSTrading Statement
18th Jun 202012:08 pmRNSSecond Price Monitoring Extn
18th Jun 202012:03 pmRNSPrice Monitoring Extension
1st Jun 202011:53 amRNSTotal Voting Rights
1st Jun 202011:43 amRNSAdditional Listing
27th May 202010:00 amRNSDirector/PDMR Shareholding
22nd May 20202:00 pmRNSDirector/PDMR Shareholding
15th May 20201:30 pmRNSDirector/PDMR Shareholding
13th May 20205:48 pmRNSDirector/PDMR Shareholding
7th May 20205:38 pmRNSDirector/PDMR Shareholding
6th May 20207:00 amRNSTrading Statement
1st May 202012:01 pmRNSTotal Voting Rights
27th Apr 202012:46 pmRNSNSM upload of Articles of Association
23rd Apr 20208:18 amRNSDividend Declaration
15th Apr 202010:00 amRNSNotice of Results
9th Apr 20202:36 pmRNSResult of AGM
9th Apr 202012:02 pmRNSPrice Monitoring Extension
9th Apr 20207:01 amRNSBob White to join Smith+Nephew’s Board as NED
9th Apr 20207:00 amRNSSmith+Nephew appoints Anne-Francoise Nesmes as CFO
6th Apr 20209:00 amRNSAdditional Annual General Meeting update
1st Apr 202012:36 pmRNSTotal Voting Rights
1st Apr 20209:30 amRNSDirector/PDMR Shareholding
30th Mar 20207:01 amRNSAnnual General Meeting update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.